TITLE

HPV and Cervical Cancer

AUTHOR(S)
Leaver, Dennis; Labonte, Geri
PUB. DATE
March 2010
SOURCE
Radiation Therapist;Spring2010, Vol. 19 Issue 1, p27
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Human papillomaviruses (HPVs) are estimated to cause a half million cases of cervical cancer worldwide each year. This article reviews the connection between HPVs and cervical cancer, discusses the HPV vaccine and provides an overview of cervical cancer symptoms, staging and treatment. Case studies also are presented.
ACCESSION #
48656790

 

Related Articles

  • HPV vaccine: One, two, or three doses for cervical cancer prevention? Mishra, Gauravi A.; Pimple, Sharmila A.; Shastri, Surendra S. // Indian Journal of Medical & Paediatric Oncology;Oct-Dec2015, Vol. 36 Issue 4, p201 

    The authors reflect on the availability of human papilloma virus (HPV) vaccines for preventing cervical cancers. Topics discussed include the prevalence of the disease, the efficacy of HPV vaccination as a primary prevention tool, and the outcome of the vaccine's three-dose schedule. Also...

  • Cervical Cancer: commercial opportunities likely to remain despite preventative potential.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p40 

    Discusses commercial opportunities in the area of cervical cancer treatment. Identification of human papillomavirus infection as the main cause of cervical cancer; Initiation of public health programs for cervical cancer to facilitate early diagnosis and treatment of the condition; Mass...

  • Human Papillomavirus Vaccines. Chebib, Ivan; Duggan, Máire A. // Canadian Journal of Pathology;2010, Vol. 2 Issue 4, p24 

    Persistent infection with human papillomavirus (HPV) is the leading cause of cervical cancer and its precursor lesions, and the widespread use of cervical cytology screening has been a major factor in the control of this tumour in Canada. Primary prevention of cervical cancer through...

  • Gardasil Again Denied Approval for Women 27-45.  // Clinical Infectious Diseases;3/1/2009, Vol. 48 Issue 5, piv 

    The article reports on the approval for the use of Merck & Co. Inc.'s Gardasil cervical cancer vaccine by women aged 27-45. It is stated that Gardasil's efficacy drops once females have been exposed to human papilloma virus (HPV). However, analyst Tim Anderson mentions that Merck could have...

  • CERVARIX.  // Monthly Prescribing Reference;Dec2009, Vol. 25 Issue 12, pA10 

    The article offers information on Cervarix vaccine from GlaxoSmithKline. Cervarix has an active ingredient of bivalent human papillomavirus (HPV) vaccine types 16 and 18 vaccine. The drug is used to prevent cervical cancer and cervical intraepithelial neoplasia (CIN) grade 1 in females 10-25...

  • HPV jab is beneficial even after Ca treatment.  // Pulse;4/4/2012, Vol. 72 Issue 12, p9 

    The article focuses on the benefits of human papilloma virus (HPV) vaccination among women even after cervical cancer treatment, according to a research led by doctor Elmar Joura.

  • Share the Word during National Immunization Month: HPV Vaccine Saves Lives. Culwell, Kelly // La Prensa San Diego;8/8/2014, Vol. 38 Issue 32, p4 

    The article offers the author's view on the importance of undergoing routine vaccination of human papilloma virus (HPV) vaccine to prevent HPV and cervical cancer.

  • Reduced acquisition and reactivation of human papillomavirus infections among older women treated with cryotherapy: results from a randomized trial in South Africa. Taylor, Sylvia; Wang, Chunhui; Wright, Thomas C.; Denny, Lynette; Tsai, Wei-Yann; Kuhn, Louise // BMC Medicine;2010, Vol. 8, p40 

    Background: Treatment of women for high-grade cervical cancer precursors frequently results in clearance of the associated high-risk human papillomavirus (hrHPV) infection but the role of treatment among women without hrHPV is unknown. We investigated whether cervical cryotherapy reduces newly...

  • A Promising DNA Methylation Signature for the Triage of High-Risk Human Papillomavirus DNA-Positive Women. Hansel, Alfred; Steinbach, Daniel; Greinke, Christiane; Schmitz, Martina; Eiselt, Juliane; Scheungraber, Cornelia; Gajda, Mieczyslaw; Hoyer, Heike; Runnebaum, Ingo B.; Dürst, Matthias // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    High-risk human papillomavirus (hrHPV)-DNA testing is frequently performed parallel to cytology for the detection of high-grade dysplasia and cervical cancer particularly in women above 30 years of age. Although highly sensitive, hrHPV testing cannot distinguish between HPV-positive women with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics